AE Wealth Management Boosts Amgen Holdings by 21.7%

Institutional investor increases stake in biotech giant in Q4 2025

Apr. 17, 2026 at 7:14am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking metal gears and machinery, representing the financial infrastructure and institutional investment behind a major biotech company.Institutional investors closely monitor the holdings and performance of major biotech firms like Amgen, which can signal broader market trends.Thousand Oaks Today

AE Wealth Management LLC, an institutional investor, increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 21.7% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 134,132 shares of the medical research company's stock, valued at $43.9 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a diverse portfolio of innovative medicines. Institutional investors closely monitor Amgen's performance and ownership changes, as it can signal broader market trends and investor sentiment around the stock.

The details

AE Wealth Management LLC added 23,909 shares of Amgen to its portfolio during the fourth quarter, bringing its total holdings to 134,132 shares. The firm's total investment in Amgen is now valued at $43.9 million. This increase in ownership comes as Amgen's stock price has risen over the past year, with the company's shares trading between $261.43 and $391.29 during that time period.

  • AE Wealth Management LLC filed its Q4 2025 13F report with the SEC on April 17, 2026.
  • The firm increased its Amgen holdings during the fourth quarter of 2025.

The players

AE Wealth Management LLC

An institutional investment firm that manages over $43.9 million in Amgen stock.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

AE Wealth Management's increased stake in Amgen reflects the biotech firm's strong performance and investor confidence in its pipeline of innovative medicines. As a major institutional investor, AE Wealth Management's moves can provide insights into broader market trends around the pharmaceutical industry.